Please login to the form below

Not currently logged in
Email:
Password:

M7824

This page shows the latest M7824 news and features for those working in and with pharma, biotech and healthcare.

Immuno-oncology at ASCO: survival data, combinations and new indications

Immuno-oncology at ASCO: survival data, combinations and new indications

Also on the agenda are preliminary clinical results with M7824, an investigational TGF‑ beta trap/anti-PD-L1 bi-functional immunotherapy fusion protein in human papillomavirus (HPV)-associated cancers and

Latest news

  • Merck takes novel immuno-oncology drug into clinical trials Merck takes novel immuno-oncology drug into clinical trials

    The bifunctional immunotherapy - called M7824 - was one of the highlights of an R&D update held yesterday at which the company highlighted its pipeline of new drug candidates in its three ... rate. Merck is not ready to divulge the molecular targets for

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics